Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | ESR1 | P03372 | 3/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | F13A1 | P00488 | 1/20 | 0.41 |
| ▸ | SLC13A5 | Q86YT5 | 2/20 | 0.41 |
| ▸ | ESRRG | P62508 | 4/20 | 0.40 |
| ▸ | ESRRB | O95718 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25596188 | 0.83 | F2RL1 (0.47) | — | |
| SCHEMBL25596779 | 0.77 | BLM (0.47) | BLMESR1ESR2KDM4EF13A1 | |
| SCHEMBL22033166 | 0.77 | BLM (0.47) | BLMESR1ESR2KDM4EF13A1 | |
| SCHEMBL31563005 | 0.76 | BLM (0.69) | BLMESR1ESR2KDM4EF13A1 | |
| SCHEMBL5004593 | 0.74 | BLM (0.67) | BLMESR1ESR2KDM4EF13A1 | |
| SCHEMBL24440186 | 0.73 | GRM2 (0.47) | KDM4ESLC13A5 | |
| SCHEMBL30483336 | 0.72 | BLM (0.50) | BLMESR1ESR2KDM4EF13A1 | |
| SCHEMBL27550853 | 0.72 | BLM (0.50) | BLMESR1ESR2KDM4EF13A1 | |
| SCHEMBL31589391 | 0.72 | ESR1 (0.54) | BLMESR1ESR2KDM4ECA2 | |
| SCHEMBL6025 | 0.72 | SLC6A2 (0.55) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230181493-A1 | BIOMARKERS RELATED TO PARKINSON'S DISEASE AND METHODS OF USING THE SAME | SENDA BIOSCIENCES INC (US) | 2023-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230181493-A1 | BIOMARKERS RELATED TO PARKINSON'S DISEASE AND METHODS OF USING THE SAME | COMT, SNCA, PARK7 | BLM 3756/4885ESR1 4421/4885ESR2 4494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.